Diagnosis and management of pulmonary arterial hypertension

Pulmonary Medicine

Volumn , Issue , 2011, Pages

  Houtchens, Jeanne ^a   Martin, Douglas ^a   Klinger, James R ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; AMBRISENTAN; AMINOTRANSFERASE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; HEMOGLOBIN; HYDRALAZINE; ILOPROST; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST; VASODILATOR AGENT;

AMINOTRANSFERASE BLOOD LEVEL; ARTERIOLE; BLEEDING; BONE PAIN; CELLULITIS; CLINICAL FEATURE; CONTINUOUS INFUSION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART CATHETERIZATION; HEMOGLOBIN BLOOD LEVEL; HOT FLUSH; HUMAN; INJECTION SITE PAIN; JAW PAIN; LIVER TOXICITY; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; PNEUMOTHORAX; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RARE DISEASE; REVIEW; SEPSIS; SIDE EFFECT; SYMPTOM; SYNCOPE; TERATOGENICITY; TREATMENT OUTCOME;

EID: 84857866666     PISSN: 20901836     EISSN: 20901844     Source Type: Journal    
DOI: 10.1155/2011/845864     Document Type: Review

References (57)

1. Tuder R. M., Abman S. H., Braun T., Capron F., Stevens T., Thistlethwaite P. A., Haworth S. G., Development and pathology of pulmonary hypertension Journal of the American College of Cardiology 2009 54 1 supplement 1 S3 S9
2. D'Alonzo G. E., Barst R. J., Ayres S. M., Survival in patients with primary pulmonary hypertension: results from a national prospective registry Annals of Internal Medicine 1991 115 5 343 349
3. Deng Z., Morse J. H., Slager S. L., Cuervo N., Moore K. J., Venetos G., Kalachikov S., Cayanis E., Fischer S. G., Barst R. J., Hodge S. E., Knowles J. A., Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene American Journal of Human Genetics 2000 67 3 737 744 (Pubitemid 30659603)
4. Lane K. B., Machado R. D., Pauciulo M. W., Thomson J. R., Phillips J. A. III, Loyd J. E., Nichols W. C., Trembath R. C., Heterozygous germline mutations in BMPR2, encoding a TGF- receptor, cause familial primary pulmonary hypertension. The International PPH consortium Nature Genetics 2000 26 1 81 84
5. Christman B. W., McPherson C. D., Newman J. H., King G. A., Bernard G. R., Groves B. M., Loyd J. E., An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension The New England Journal of Medicine 1992 327 2 70 75
6. Giaid A., Yanagisawa M., Langleben D., Michel R. P., Levy R., Shennib H., Kimura S., Masaki T., Duguid W. P., Stewart D. J., Expression of endothelin-1 in the lungs of patients with pulmonary hypertension The New England Journal of Medicine 1993 328 24 1732 1739 (Pubitemid 23170122)
7. Rubens C., Ewert R., Halank M., Wensel R., Orzechowski H. D., Schultheiss H. P., Hoeffken G., Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension Chest 2001 120 5 1562 1569 (Pubitemid 33078473)
8. Giaid A., Saleh D., Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension The New England Journal of Medicine 1995 333 4 214 221
9. Kharitonov S. A., Cailes J. B., Black C. M., du Bois R. M., Barnes P. J., Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension Thorax 1997 52 12 1051 1055 (Pubitemid 27515784)
10. Hanson K. A., Ziegler J. W., Rybalkin S. D., Miller J. W., Abman S. H., Clarke W. R., Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity American Journal of Physiology 1998 275 5 L931 L941
11. Simonneau G., Robbins I. M., Beghetti M., Updated clinical classification of pulmonary hypertension Journal of the American College of Cardiology 2009 54 1 supplement 1 S43 S54
12. Humbert M., Sitbon O., Chaouat A., Bertocchi M., Habib G., Gressin V., Yaici A., Weitzenblum E., Cordier J. F., Chabot F., Dromer C., Pison C., Reynaud-Gaubert M., Haloun A., Laurent M., Hachulla E., Simonneau G., Pulmonary arterial hypertension in France: results from a national registry American Journal of Respiratory and Critical Care Medicine 2006 173 9 1023 1030
13. Peacock A. J., Murphy N. F., McMurrey J. J., Caballero L., Stewart S., An epidemiological study of pulmonary arterial hypertension European Respiratory Journal 2007 30 1 104 109 (Pubitemid 47074013)
14. Badesch D. B., Raskob G. E., Elliott C. G., Krichman A. M., Farber H. W., Frost A. E., Barst R. J., Benza R. L., Liou T. G., Turner M., Giles S., Feldkircher K., Miller D. P., McGoon M. D., Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry Chest 2010 137 2 376 387
15. Bull T. M., Physical exam in pulmonary arterial hypertension Advances in Pulmonary Hypertension 2005 4 6 10
16. Leuchte H. H., Holzapel M., Baumgartner R. A., Clinical significance of brain natriurectic peptide in primary pulmonary hypertension Journal of the American College of Cardiology 2004 43 5 764 770 (Pubitemid 38296473)
17. Forfia P. R., Mathai S. C., Fisher M. R., Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension American Journal of Respiratory and Critical Care Medicine 2008 177 12 1364 1369 (Pubitemid 351860914)
18. Bossone E., Citro R., Blasi F., Allegra L., Echocardiography in pulmonary arterial hypertension: an essential tool Chest 2007 131 2 339 341 (Pubitemid 46280389)
19. Arcasoy S. M., Christie J. D., Ferrare V. A., Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease American Journal of Respiratory and Critical Care Medicine 2003 167 5 735 740 (Pubitemid 36801751)
20. Hinderliter A. L., Willis P. W. IV, Long W., Clarke W. R., Ralph D., Caldwell E. J., Williams W., Ettinger N. A., Hill N. S., Summer W. R., de Biosblanc B., Koch G., Li S., Clayton L. M., Jbsis M. M., Crow J. W., Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. PPH study group. Primary pulmonary hypertension American Journal of Cardiology 1999 84 4 481 484 (Pubitemid 29398678)
21. McLaughlin V. V., Archer S. L., Badesch D. B., Barst R. J., Farber H. W., Lindner J. R., Mathier M. A., Mc Goon M. D., Park M. H., Rosenson R. S., Rubin L. J., Tapson V. F., Varga J., ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation task force on expert consensus documents Journal of the American College of Cardiology 2009 53 17 1573 1619
22. Rich S., Kaufmann E., Levy P. S., The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension The New England Journal of Medicine 1992 327 2 76 81
23. Sitbon O., Humbert M., Jas X., Ioos V., Hamid A. M., Provencher S., Garcia G., Parent F., Hervé P., Simonneau G., Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension Circulation 2005 111 23 3105 3111 (Pubitemid 40847788)
24. Ichinose F., Erana-Garcia J., Hromi J., Raveh Y., Jones R., Krim L., Clark M. W., Winkler J. D., Bloch K. D., Zapol W. M., Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension Critical Care Medicine 2001 29 5 1000 1005 (Pubitemid 32424353)
25. Wilkens H., Guth A., Knig J., Forestier N., Cremers B., Hennen B., Bhm M., Sybrecht G. W., Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension Circulation 2001 104 11 1218 1222 (Pubitemid 32848108)
26. Michelakis E., Tymchak W., Lien D., Webster L., Hashimoto K., Archer S., Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide Circulation 2002 105 20 2398 2403 (Pubitemid 34556392)
27. Galie N., Ghofrani H. A., Torbicki A., Sildenafil citrate therapy for pulmonary arterial hypertension The New England Journal of Medicine 2005 353 20 2148 2157 (Pubitemid 41653106)
28. Galie N., Brundage B. H., Ghofrani H. A., Tadalafil therapy for pulmonary arterial hypertension Circulation 2009 119 22 2894 2903
29. Gomberg-Maitland M., Olschewski H., Prostacyclin therapies for the treatment of pulmonary arterial hypertension European Respiratory Journal 2008 31 4 891 901
30. Jones D. K., Higenbottam T. W., Wallwork J., Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin) British Heart Journal 1987 57 3 270 278 (Pubitemid 17039355)
31. Rubin L. J., Mendoza J., Hood M., McGoon M., Barst R., Williams W. B., Diehl J. H., Crow J., Long W., Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol) Annals of Internal Medicine 1990 112 7 485 491 (Pubitemid 20100285)
32. Barst R. J., Rubin L. J., Long W. A., Mcgoon M. D., Rich S., Badesch D. B., Groves B. M., Tapson V. F., Bourge R. C., Brundage B. H., Koerner S. K., Langleben D., Keller C. A., Murali S., Uretsky B. F., Clayton L. M., Jbsis M. M., Blackburn S. D., Shortino D., Crow J. W., A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension The New England Journal of Medicine 1996 334 5 296 301 (Pubitemid 26033085)
33. Menon N., McAlpine L., Peacock A. J., Madhok R., The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis Arthritis and Rheumatism 1998 41 3 466 469 (Pubitemid 28128772)
34. Humbert M., Sanchez O., Fartoukh M., Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin) Chest 1998 114, supplement 1 80S 82S (Pubitemid 28334880)
35. Badesch D. B., Tapson V. F., McGoon M. D., Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease Annals of Internal Medicine 2000 132 6 425 434 (Pubitemid 30149039)
36. McLaughlin V. V., Barst R. J., Rich S., Efficacy and safety of UT-15, a prostacyclin analogue for primary pulmonary hypertension European Heart Journal 1990 20 486
37. Gaine S. P., Oudiz R., Rich S., Acute hemodynamic effects of 15AU81, a stable prostacyclin analogue, in severe primary pulmonary hypertension American Journal of Respiratory and Critical Care Medicine 1998 157 A595
38. Simonneau G., Barst R. J., Galie N., Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension American Journal of Respiratory and Critical Care Medicine 2002 165 6 800 804 (Pubitemid 34229650)
39. Gomberg-Maitland M., Tapson V. F., Benza R. L., McLaughlin V. V., Krichman A., Widlitz A. C., Barst R. J., Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension American Journal of Respiratory and Critical Care Medicine 2005 172 12 1586 1589 (Pubitemid 43076550)
40. Olschewski H., Simonneau G., Galie N., Inhaled iloprost for severe pulmonary hypertension The New England Journal of Medicine 2002 347 5 22 29
41. Voswinckel R., Enke B., Reichenberger F., Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies Journal of the American College of Cardiology 2006 48 8 1672 1681 (Pubitemid 44528194)
42. Voswinckel R., Ghofrani H. A., Inhaled treprostinil for treatment of chronic pulmonary arterial hypertension Annals of Internal Medicine 2006 144 2 149 150 (Pubitemid 46768245)
43. McLaughlin V. V., Benza R. L., Rubin L. J., Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension Journal of the American College of Cardiology 2010 55 18 1915 1922
44. Hickey K. A., Rubanyi G., Paul R. J., Highsmith R. F., Characterization of a coronary vasoconstrictor produced by cultured endothelial cells American journal of physiology 1985 248 5 C550 C556
45. Yanagisawa M., Kurihara H., Kimura S., A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 1988 332 411 415 (Pubitemid 18090241)
46. Channick R. N., Simonneau G., Sitbon O., Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study The Lancet 2001 358 9288 1119 1123 (Pubitemid 32971843)
47. Rubin L. J., Badesch D. B., Barst R. J., Bosentan therapy for pulmonary arterial hypertension The New England Journal of Medicine 2002 346 12 896 903 (Pubitemid 34984638)
48. Galie N., Olschewski H., Oudiz R. J., Ambrisentan for the treatment of pulmonary arterial hypertension Circulation 2008 117 23 3010 3019
49. Wilkins M. R., Paul G. A., Strange J. W., Tunariu N., Gin-Sing W., Banya W. A., Westwood M. A., Stefanidis A., Ng L. L., Pennell D. J., Mohiaddin R. H., Nihoyannopoulos P., Gibbs J. S., Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study American Journal of Respiratory and Critical Care Medicine 2005 171 11 1292 1297 (Pubitemid 40740738)
50. Barst R. J., Gibbs J. S., Ghofrani H. A., Hoeper M. M., McLaughlin V. V., Rubin L. J., Sitbon O., Tapson V. F., Gali N., Updated evidence-based treatment algorithm in pulmonary arterial hypertension Journal of the American College of Cardiology 2009 54 1 supplement 1 S78 S84
51. Simonneau G., Rubin L. J., Galie N., Barst R. J., Fleming T. R., Frost A. E., Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial Annals of Internal Medicine 2008 149 8 521 530
52. Humbert M., Barst R. J., Robbins I. M., Channick R. N., Galie N., Boonstra A., Combination of bosentan with epoprostenol in pulmonary arterial hypertension: breath-2 European Respiratory Journal 2004 24 3 353 359 (Pubitemid 39232254)
53. McLaughlin V. V., Oudiz R. J., Frost A., Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension American Journal of Respiratory and Critical Care Medicine 2006 174 11 1257 1263 (Pubitemid 44924827)
54. A study of first line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH). http://clinicaltrials.gov
55. Badesch, ACCP clinical practice guidelines Chest 2004 126S 35S 62S
56. Rich S., Seidlitz M., Dodin E., Osimani D., Judd D., Genthner D., McLaughlin V., Francis G., The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension Chest 1998 114 3 787 792 (Pubitemid 28433741)
57. Roberts D. H., Lepore J. J., Maroo A., Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension Chest 2001 120 5 1547 1555 (Pubitemid 33078471)